In managing functional dyspepsia, itopride and acotiamide, tricyclic antidepressants, histamine‐2 receptor antagonists, proton pump inhibitors, and the antipsychotic sulpiride or levosulpiride all prove to be more effective than placebo, according to the results of a meta-analysis.
Diabetes, hypertension, and older age are associated with lower hospital readmission in patients with gastroparesis, while higher length of stay (LOS), drug abuse, and marijuana use increase the 30-day readmission rate, a study has shown.
Administering extended doses of mirikizumab for an additional 12 weeks successfully produces a clinical response in up to 50 percent of ulcerative colitis (UC) patients who did not benefit from 12 weeks of induction doses, according to the results of a phase II trial.
Treatment with infliximab to control inflammation effectively reduces parameters that are associated with a higher risk of venous thromboembolism in patients with inflammatory bowel disease (IBD), results of a study have shown.
In the treatment of patients with inflammatory bowel disease (IBD), comorbidities, but not patient age, influence the risk of any infection or hospitalizations on either vedolizumab or ustekinumab, a study suggests.
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.